Evidence map›Paper›PMID 33073177›Full record

ReviewMayo Clinic proceedings. Innovations, quality & outcomes2020

Time to Treat: Applying Lessons Learned from Other Viral Syndromes to SARS-CoV-2.

Ryan W Stevens, Christina G Rivera, Omar Abu Saleh

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Mayo Clinic proceedings. Innovations, quality & outcomes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ryan W StevensDepartment of Pharmacy Services, Mayo Clinic, Rochester, MN.
Christina G RiveraDepartment of Pharmacy Services, Mayo Clinic, Rochester, MN.
Omar Abu SalehDivision of Infectious Disease, Mayo Clinic, Rochester, MN.
Mayo Clinic in Arizona · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In many different infectious syndromes, most notably several viral conditions, time to therapy initiation from symptom onset has been identified as a critical component contributing to the success of therapy. Regarding COVID-19, several therapeutic antivirals, both repurposed and novel, have been evaluated for overall safety and efficacy. As the literature related to these therapies has expanded recently, a wide array of trial designs, time to therapy initiation thresholds, and clinical outcomes in regard to time to initiation have been reported. We describe the potential effects of time to therapy initiation on outcomes in patients with COVID-19 and detail the existing data surrounding this topic in relation to remdesivir, convalescent plasma, lopinavir/ritonavir, and hydroxychloroquine.

Indexed as

COVID-19, coronavirus infectious disease 2019CPT, convalescent plasma therapyIg, immunoglobulinIQR, interquartile rangeLPV/r, lopinavir/ritonavirSARS-CoV-1, severe acute respiratory syndrome coronavirus 1SARS-CoV-2, severe acute respiratory syndrome coronavirus 2

Identifiers

PMID33073177
PMCPMC7550090
OpenAlexW3091997167

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.